Literature DB >> 33460505

Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1.

W Cantrell1, P Lee2, A M Mendelsohn3, S J Rozzo3, W Liao4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33460505     DOI: 10.1111/jdv.17124

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  2 in total

1.  Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review.

Authors:  Marie Masson Regnault; Jason Shourick; Fatma Jendoubi; Marie Tauber; Carle Paul
Journal:  Am J Clin Dermatol       Date:  2022-04-30       Impact factor: 6.233

Review 2.  Biologic Treatments of Psoriasis: An Update for the Clinician.

Authors:  Nicholas D Brownstone; Julie Hong; Megan Mosca; Edward Hadeler; Wilson Liao; Tina Bhutani; John Koo
Journal:  Biologics       Date:  2021-02-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.